The Chemours Company
CCBusiness Overview
source: coverage-next-full ticker: CC step: "01" title: Business Overview — Chemours Company created: 2026-05-29
Step 01: Business Overview
Company Summary
The Chemours Company (NYSE: CC) is a global chemistry company producing fluorochemicals, titanium dioxide pigments, and specialty industrial chemicals. Spun off from DuPont in 2015 with approximately $6.2 billion in revenues, Chemours has since restructured its portfolio around three core segments. The company serves customers in coatings, plastics, refrigeration/HVAC, electronics, mining, and industrial markets across more than 100 countries.
Chemours' strategic identity is bifurcated: the Titanium Technologies segment is a large-volume commodity business subject to intense cyclical swings, while the Thermal & Specialized Solutions segment — anchored by Opteon HFO refrigerants — is the company's most valuable franchise, possessing structural growth drivers and pricing power that the TiO2 segment lacks.
Segment Detail
1. Titanium Technologies (~45% of Revenue)
Product: Ti-Pure titanium dioxide (TiO2) pigments End Markets: Architectural and industrial paints/coatings (~50% of TiO2 demand), plastics (~25%), paper/laminates, cosmetics, and other specialty applications Global Position: One of the top three global TiO2 producers by volume, alongside Tronox (TROX) and Venator Materials. Chemours operates the world's largest TiO2 plant in New Johnsonville, Tennessee (chloride process), giving it significant cost advantages vs. sulfate-process producers.
Key Dynamics:
- TiO2 is a commodity-like product — demand is highly correlated with global construction/paint activity
- The chloride process Chemours uses is more cost-efficient and produces higher-brightness TiO2 vs. sulfate competitors (particularly Chinese producers)
- Chinese overcapacity in sulfate-process TiO2 is a persistent price headwind
- Paint & coatings companies (Sherwin-Williams, PPG, AkzoNobel) are large customers and exert pricing pressure
- TiO2 pricing cycles typically last 3-5 years; the 2022-2024 period was a deep down-cycle driven by post-COVID destocking and China import pressure
Brands: Ti-Pure, including Ti-Pure TS-6200 and Ti-Pure R-960 grades Manufacturing: Plants in New Johnsonville, TN; DeLisle, MS; Altamira, Mexico; Kuan Yin, Taiwan; Uberaba, Brazil; Edge Moor, DE (legacy)
2. Thermal & Specialized Solutions (~35% of Revenue)
Products:
- Opteon HFO Refrigerants — Next-generation low global warming potential (GWP) refrigerants for automotive air conditioning (Opteon YF / HFO-1234yf), stationary HVAC (Opteon XP series), and commercial refrigeration
- Freon HFC Refrigerants — Legacy high-GWP refrigerants (R-410A, R-134a, R-22 blends); being phased down globally
- Other: Foam blowing agents, aerosol propellants, fire suppression chemicals
Key Dynamics:
- Opteon YF is the dominant mobile air conditioning refrigerant for new vehicles globally, with Chemours holding ~70-80% global market share in HFO-1234yf. Honeywell (Solstice) holds most of the remainder.
- The EPA AIM Act (American Innovation and Manufacturing Act, 2020) mandates an 85% phasedown of HFC production/consumption by 2036. This is a structural tailwind forcing the market toward Opteon HFOs.
- EU F-Gas Regulation similarly phases down HFCs, driving European adoption of Opteon.
- Opteon commands premium pricing vs. legacy HFCs due to environmental performance and regulatory compliance.
- Freon legacy HFCs generate cash as they decline; Opteon replaces that volume at higher margins.
Brands: Opteon (HFOs), Freon (HFCs), Vertrel (precision cleaning) Manufacturing: Corpus Christi, TX (primary HFO production); Fayetteville Works, NC (PFAS-linked legacy facility)
3. Performance Solutions (~20% of Revenue)
Products:
- Mining Chemicals: Sodium cyanide (NaCN) for gold mining (cyanidation process) — Chemours is one of the world's largest producers
- Fluoropolymers: Teflon-based PTFE and FEP for industrial applications (wire insulation, chemical processing equipment, cookware coatings)
- Water Treatment: Specialty chemicals
- Other Specialty: Chemical intermediates, agricultural chemicals
Key Dynamics:
- Sodium cyanide demand tracks gold mining activity — relatively stable with commodity gold price correlation
- Fluoropolymers face potential regulatory risk due to PFAS concerns (PTFE itself is not classified as PFAS but precursors and processing aids have PFAS exposure)
- Segment margins are more stable than TiO2 but less attractive than Opteon
Key Brands
| Brand | Segment | Position |
|---|---|---|
| Ti-Pure | Titanium Technologies | Top-3 global TiO2 producer |
| Opteon | Thermal & Specialized Solutions | #1 HFO-1234yf globally (~75% share) |
| Freon | Thermal & Specialized Solutions | Legacy brand, declining |
| Teflon / Zonyl | Performance Solutions | Recognized fluoropolymer brand |
| Cyanco | Performance Solutions | Major sodium cyanide brand |
Leadership
- CEO: Denise Dignam (appointed April 2023; previously SVP of Titanium Technologies)
- CFO: Shane Hostetter (appointed following 2023-2024 restatement-related departures)
- Board: 9 directors; independent chair
Geographic Revenue Mix
- Americas: ~45-50% of revenues
- Asia Pacific: ~25-30%
- Europe / Middle East / Africa: ~20-25%
Investment Thesis Summary
Chemours is a tale of two companies: a struggling commodity TiO2 business weighed down by a global down-cycle and Chinese overcapacity, and a premium Opteon refrigerant franchise with structural regulatory tailwinds. The key investor debate is whether Opteon's durable earnings power — compounding as HFC phasedowns accelerate globally — can offset (1) TiO2 commodity risk, (2) PFAS liability overhang, and (3) elevated financial leverage from the original spinoff and settlement funding.
Financial Snapshot
source: coverage-next-full ticker: CC step: "04" title: Financial Snapshot — 3-Year P&L and Key Metrics created: 2026-05-29
Step 04: Financial Snapshot
Income Statement Summary (FY2021-FY2023)
| Metric | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Revenue | $6.3B | $6.8B | ~$5.2B |
| Gross Profit | ~$1.9B | ~$2.0B | ~$1.1B |
| Gross Margin | ~30% | ~29% | ~21% |
| Adj. EBITDA | ~$1.3B | ~$1.4B | ~$700-800M |
| Adj. EBITDA Margin | ~21% | ~21% | ~13-15% |
| EBIT (Operating Income) | ~$950M | ~$1.0B | ~$300-400M |
| EBIT Margin | ~15% | ~15% | ~6-8% |
| Net Interest Expense | ~$200M | ~$220M | ~$250M |
| Adj. Net Income | ~$600M | ~$700M | ~$100-200M |
| GAAP Net Income | ~$400M | ~$500M | ~($100-200M) loss |
| Adj. EPS (diluted) | ~$3.70 | ~$4.30 | ~$0.70-1.20 |
Note: FY2023 figures are approximate due to ongoing accounting restatement; actual restated figures may differ. FY2024 data not yet fully available at time of analysis.
Key Drivers of FY2022 → FY2023 Decline
The collapse in reported earnings from FY2022 to FY2023 was driven by:
TiO2 Volume Decline: Approximately 20-25% volume reduction as paint/coatings customers aggressively destocked post-COVID. Volumes fell from ~860 kMT (FY2022) to approximately 680-700 kMT (FY2023).
TiO2 Price Decline: Average selling prices fell approximately 15-20% from FY2022 peaks as Chinese import pressure intensified and customers pushed back on price.
PFAS Settlement Charge: Recognition of the $592M water utility settlement contribution created a significant one-time charge in FY2023.
Fixed Cost Deleverage: TiO2 plants have high fixed cost bases; volume declines translate to significant operating leverage losses.
Raw Material / Energy Costs: Energy and feedstock (TiO2 ore / ilmenite and rutile) costs remained elevated even as selling prices fell.
Margin Bridge: FY2022 → FY2023
| Bridge Item | EBITDA Impact |
|---|---|
| TiO2 volume decline | -$400 to -$500M |
| TiO2 price decline | -$250 to -$350M |
| TSS (Opteon) growth offset | +$100 to +$150M |
| Cost reductions / restructuring | +$50 to +$100M |
| PFAS settlement | -$150 to -$200M (partial-year recognition) |
| Net Change | -$600 to -$700M |
Key Margin Analysis
Gross Margin
Chemours' gross margin is heavily TiO2-cycle dependent. During the 2021-2022 upcycle, blended gross margins reached 28-30%. During the 2023-2024 down-cycle trough, margins fell toward 18-22%. The margin floor reflects: (1) TSS segment (Opteon) maintaining healthy margins, (2) partial fixed cost absorption even at low TiO2 volumes.
TSS Gross Margin: Estimated 35-45% (not separately disclosed; inferred from segment EBITDA margins) TiO2 Gross Margin: Estimated 15-25% at mid-cycle; compressed to <10% at trough volumes/prices PS Gross Margin: Estimated 20-30% (stable, niche positions)
EBITDA Margin
Adj. EBITDA margin is the most relevant operating metric for Chemours given its significant D&A from capital-intensive fluorochemical and TiO2 plants. Through-the-cycle EBITDA margin target (management guidance) is approximately 18-22%, achievable only with TiO2 recovery + Opteon growth.
Net Margin
Net margin is highly distorted by (1) interest expense on $3.5-4B net debt, (2) PFAS charges, and (3) accounting restatement items. GAAP net income is not a reliable earnings metric at this stage.
Free Cash Flow
| Metric | FY2021 | FY2022 | FY2023 |
|---|---|---|---|
| Adj. EBITDA | ~$1.3B | ~$1.4B | ~$750M |
| CapEx | ~$300M | ~$350M | ~$350M |
| Cash Interest | ~$180M | ~$200M | ~$230M |
| Cash Taxes | ~$150M | ~$180M | ~$50M |
| Working Capital Change | +/- varies | +$50M | -$50M |
| Levered FCF (approx) | ~$620M | ~$620M | ~$70-120M |
| PFAS / Settlement Cash Payments | Minimal | Minimal | ~$100-150M |
| Net FCF after PFAS | ~$620M | ~$620M | ~($30-80M) |
FCF generation collapsed in FY2023 primarily due to EBITDA compression, not capital structure changes. At mid-cycle EBITDA levels ($1.0-1.2B), Chemours can generate $500-700M in levered FCF — sufficient to service debt, fund PFAS settlements, and begin returning capital.
Balance Sheet Snapshot (FY2023)
| Item | Amount |
|---|---|
| Total Assets | ~$5.5-6.0B |
| Cash & Equivalents | ~$750-900M |
| Total Debt | ~$4.0-4.5B |
| Net Debt | ~$3.0-3.5B |
| Shareholders' Equity | ~$0-200M (near-zero due to PFAS charges + buybacks in prior years) |
Leverage: Net Debt / Adj. EBITDA was approximately 4.0-5.0x at the FY2023 trough — elevated and near stress territory for a commodity chemicals company.
Accounting Restatement Impact
Chemours disclosed in 2023 that certain accounting irregularities related to supplier agreements and working capital timing required financial restatement. The restatement:
- Primarily affected timing of certain revenue and expense recognition
- Did not materially alter segment-level economics
- Led to CFO departure and increased scrutiny from auditors
- Created delays in SEC filings and investor uncertainty
The restatement impact on reported EBITDA is estimated at a few tens of millions of dollars — significant for credibility but not indicative of fundamental fraud at scale. The new CFO (Shane Hostetter) and audit committee overhaul are intended to address control weaknesses.
Credit Profile
| Metric | Status |
|---|---|
| Moody's Rating | B1 (Speculative Grade) |
| S&P Rating | BB- (Sub-Investment Grade) |
| Primary Covenants | Net Leverage covenant (~4.5-5.0x ceiling) |
| Maturity Profile | Laddered 2026-2031; Term Loan B + Senior Notes |
| Liquidity | ~$1.5-2.0B (cash + revolver availability) |
The credit rating reflects elevated leverage, PFAS liability uncertainty, and TiO2 cyclicality. Chemours is currently investment-grade-aspiring but dependent on TiO2 recovery and Opteon cash flow growth to sustain covenant compliance.
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $CC.